Figure 6 Double opposed-field irradiation of an idealized geometry

Slides:

Advertisements

Similar presentations

Some remaining questions in particle therapy radiation biology Bleddyn Jones University of Oxford 1. Gray Institute for Radiation Oncology & Biology 2.

Advertisements

Tumour Therapy with Particle Beams Claus Grupen University of Siegen, Germany [physics/ ] Phy 224B Chapter 20: Applications of Nuclear Physics 24.

Study of the fragmentation of Carbon ions for medical applications Protons (hadrons in general) especially suitable for deep-sited tumors (brain, neck.

BIOLOGICAL EFFICIENCY OF A THERAPEUTIC PROTON BEAM: A STUDY OF HUMAN MELANOMA CELL LINE I. Petrović 1, A. Ristić-Fira 1, D. Todorović 1, L. Korićanac 1,

Heavy Ion Tumor Therapy

The Increased Biological Effectiveness of Heavy Charged Particle Radiation: From Cell Culture Experiments to Biophysical Modelling Michael Scholz GSI Darmstadt.

Mathematical Modelling within Radiotherapy: The 5 R’s of Radiotherapy and the LQ model. Helen McAneney 1 and SFC O’Rourke 1,2 1 School Mathematics and.

Karolina Kokurewicz Supervisors: Dino Jaroszynski, Giuseppe Schettino

Experimental Cave at Trento CPT: status update Francesco Tommasino RDH/IRPT Meeting – Roma, 1 Feb 2016.

RBE: open issues and next challenges Francesco Tommasino Workshop: la radiobiologia in INFN Trento, Maggio 2016.

Particle Therapy at GSI

Linear Energy Transfer and Relative Biological Effectiveness

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 3 Risk-adapted and response-adapted

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 The biological effects of charged particles

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 Algorithm for the determination of the clinical

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 2 Nonmalignant tissue can be spared from radiation

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 The yin and yang of tumour-associated

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Overcoming resistance of cancer stem cells

Figure 2 Frequency and overlap of alterations

Figure 2 Variations between planned and delivered doses of radiation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Presentation transcript:

Figure 6 Double opposed-field irradiation of an idealized geometry simulating a typical head and neck tumour using ionization from 1H, 4He, 12C, or 16O Figure 6 | Double opposed-field irradiation of an idealized geometry simulating a typical head and neck tumour using ionization from 1H, 4He, 12C, or 16O. The simulated tumour is a cube with 25 mm sides, centred in an irradiation volume with a 16 cm length. The relative biological effectiveness (RBE)-weighted dose optimizations for a radioresistant or for a radiosensitive tumour were performed using TRiP98 software (GSI Helmholtz Center for Heavy Ion Research; Darmstadt, Germany), used in treatment planning with carbon ions in Europe and China. The performance of helium, evaluated as the ratio of peak to plateau dose, was good in both sensitive and resistant tumours. As expected, heavy oxygen ions result in a higher dose irradiation of nonmalignant tissue in patients with tumours with a high α/β ratio, corresponding to high radiosensitivity (right panel), compared with tumours with a low α/β ratio (radioresistant). For the latter, the use of heavy oxygen ions can be beneficial. N, nonmalignant tissue; T, tumour. Figure adapted from Tommasino, F., Scifoni, E. & Durante, M. New ions for therapy. Int. J. Part. Ther. 2, 428–438 (2015), under a Creative Commons CC-BY licence, https://creativecommons.org/licenses/by/3.0/us/. Figure adapted from Tommasino, F., Scifoni, E. & Durante, M. New ions for therapy. Int. J. Part. Ther. 2, 428–438 (2015), under a Creative Commons CC-BY licence, https://creativecommons.org/licenses/by/3.0/us/. Durante, M. et al. (2017) Charged-particle therapy in cancer: clinical uses and future perspectives Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.30